ImmuCell Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for ImmuCell Corporation (ICCC) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
Operating Activities
Net Income-2.16-5.77-2.49-0.08-1.02-1.30-2.32
Depreciation & Amortization2.692.722.502.462.352.271.52
Deferred Income Tax0.000.000.000.00-0.010.020.46
Stock Based Compensation0.330.370.270.140.250.000.00
Change in Working Capital-0.41-2.11-1.83-1.620.53-1.100.30
Change in Accounts Receivable-1.59-0.430.94-0.90-0.160.000.00
Change in Inventory0.70-1.77-2.95-1.000.430.000.00
Change in Accounts Payable0.360.160.340.250.300.000.00
Change in Other Working Capital0.120.120.040.02-0.030.000.00
Other Operating Activities-0.150.120.290.02-0.570.330.02
Net Cash from Operating Activities0.36-4.67-1.540.951.320.23-0.37
Investing Activities
Capital Expenditures-0.47-1.893.98-2.614.071.39-2.03
Acquisitions0.000.000.000.000.000.00-0.01
Purchases of Investments0.000.000.001.001.460.000.00
Sales/Maturities of Investments0.000.000.001.001.467.670.00
Other Investing Activities0.000.000.000.000.000.000.25
Net Cash from Investing Activities-0.46-1.89-3.96-1.60-2.57-3.40-1.79
Financing Activities
Debt Repayment-1.47-3.19-0.92-0.77-9.570.00-0.40
Common Stock Issued4.650.020.034.230.000.000.00
Other Financing Activities-0.30-0.08-0.020.00-0.050.000.00
Net Cash from Financing Activities2.881.751.113.881.916.940.89
Summary
Net Change in Cash2.78-4.81-4.393.240.663.77-1.28
Cash at Beginning of Period0.985.7910.196.956.290.003.80
Cash at End of Period3.760.985.7910.196.956.292.52
Free Cash Flow-0.11-6.57-5.51-1.65-2.71-1.16-2.40
Supplemental Disclosures
Interest Paid0.530.440.340.310.480.000.40
Income Taxes Paid0.010.010.000.010.000.000.00